Niagen Bioscience (NASDAQ:NAGE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Niagen Bioscience (NASDAQ:NAGE) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

A number of other equities research analysts also recently weighed in on NAGE. Roth Capital reiterated a “buy” rating and set a $23.00 price target (up previously from $10.00) on shares of Niagen Bioscience in a research note on Friday, June 6th. Canaccord Genuity Group lifted their price target on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, June 10th. Finally, HC Wainwright lifted their price target on shares of Niagen Bioscience from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Monday, August 11th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Niagen Bioscience currently has an average rating of “Buy” and an average price target of $13.42.

Niagen Bioscience Price Performance

NAGE opened at $10.12 on Friday. Niagen Bioscience has a fifty-two week low of $3.10 and a fifty-two week high of $14.69. The firm’s fifty day moving average price is $11.50 and its two-hundred day moving average price is $8.46. The company has a market capitalization of $807.10 million, a P/E ratio of 48.19 and a beta of 2.12.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The firm had revenue of $31.12 million for the quarter, compared to the consensus estimate of $28.55 million.

Institutional Investors Weigh In On Niagen Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in NAGE. State of Wyoming acquired a new stake in shares of Niagen Bioscience in the 4th quarter valued at $39,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Niagen Bioscience in the 4th quarter valued at $53,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Niagen Bioscience in the 4th quarter valued at $67,000. ProShare Advisors LLC acquired a new stake in shares of Niagen Bioscience in the 4th quarter valued at $74,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in shares of Niagen Bioscience in the 4th quarter valued at $94,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.